On Tuesday, Shares of Bank of America Corporation (NYSE:BAC), lost -0.20% to $15.26.
The company was the recipient of a rare triple upgrade before Tuesday open. If one comprises Monday’s upgrade by KBW, who raised its rating from Market Perform to Outperform with a $20 price target that would be four over the last two days, according to Benzinga.
Both Bernstein and Baird went to an Outperform rating from a Neutral rating and Bernstein maintained its $20 price target. In addition, Macquarie went from Underperform to Neutral.
The trio of upgrades instigated a sharply higher open ($16.20 vs. Monday’s close of $15.29), but could only rally another penny before declining to $15.86. Benzinga Reports
Bank of America Corporation is a bank holding company. The company, through its auxiliaries, operates through Consumer and Business Banking; Consumer Real Estate Services; Global Wealth and Investment Administration; Global Banking; Global Markets; and Other segments.
Shares of AbbVie Inc. (NYSE:ABBV), declined -4.32% to $60.71, during its last trading session.
AbbVie has bought a priority review voucher from United Therapeutics Corp for $350 million that will allow it to accelerate the review process for one of its drugs, according to Reuters.
United Therapeutics received a rare pediatric disease priority review voucher in March after its drug, Unituxin, was approved by the U.S. Food and Drug Administration to treat neuroblastoma, the company said on Wednesday. Reuters Reports
The voucher, which offers a plethora of incentives, makes its holder eligible to have one of its drugs reviewed in six months, contrast to the standard 10 months. Reuters added.
AbbVie did not disclose its plans for the voucher.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants.
Finally, Union Pacific Corporation (NYSE:UNP), ended its last trade with -2.54% loss, and closed at $80.56.
Brokerage firm Macquarie downgrades its rating on Union Pacific Corporation (NYSE:UNP). As per the latest information, the brokerage house lowers the price target to $95 per share from a preceding target of $105. The shares have been rated Neutral. Formerly, the analysts had a Outperform rating on the shares. The rating by the firm was issued on August 20, 2015.
Union Pacific Corporation, through its partner, Union Pacific Railroad Company, operates railroads in the United States. The company offers freight transportation services for agricultural products, counting grains, commodities produced from grains, and food and beverage products; automotive products, such as finished vehicles and automotive parts; and chemicals comprising of industrial chemicals, plastics, crude oil, liquid petroleum gases, fertilizers, soda ash, sodium products, and phosphorus rock and sulfur products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
